All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @sierra.robichaud on TikTok · 69s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @sierra.robichaud's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I've been on wagobi for the last month, so I'm going to share my weights and how much
  2. 0:04I lost week by week for the last four weeks.
  3. 0:07You guys love these videos, so I'm going to continue to share them.
  4. 0:11Don't forget to hit the follow.
  5. 0:12I had gone off of wagobi for a little bit because I was getting super tired again, but
  6. 0:18I restarted along with taking liquid B vitamins that I shared with you guys and I feel so
  7. 0:24much better.
  8. 0:25These are my weights week by week and how much I lost.
  9. 0:28Don't come for me.
  10. 0:29Starting weight on May 6 was 180 pounds.
  11. 0:32Week one, I lost three pounds.
  12. 0:35I was down to 177.
  13. 0:37Week two, I lost three pounds.
  14. 0:41I was down to 174.
  15. 0:43Week three, I gained one pound, so I went up to 175.
  16. 0:49And week four, I lost three pounds and I'm down to 172.
  17. 0:54So overall, I lost eight pounds in one month, which is pretty normal for when I'm on the
  18. 0:59medication and I am on the 1.0 dose.
  19. 1:03And here's the graph I keep track of my weight because I'm a crazy person, so that's what it
  20. 1:06looks like.

Sierra's Wegovy weight loss tracking looks about right

Sierra

TikTok creator

148.2K viewsWatch on TikTok →

Quick answer

Sierra is documenting semaglutide use at the 1.0 mg dose, which sits within the standard Wegovy titration schedule that escalates from 0.25 mg up to the maintenance dose of 2.4 mg over several months. Her reported 8-pound loss over four weeks is plausible for an early treatment period, particularly given she was restarting after a gap, when appetite suppression effects can temporarily intensify. Her self-reported fatigue, which prompted a previous discontinuation, is a recognized side effect of GLP-1 receptor agonists and typically relates to caloric restriction and GI adaptation rather than a nutritional deficiency.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion
Start provider reviewReview Compounded Semaglutide

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Sierra's Wegovy weight loss tracking looks about right, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Start the provider review

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Helpful context before the funnel

Semaglutide video claims video hub

Compare nearby social claims before acting.

Review Compounded Semaglutide

Move from claim context to product, safety, and access details.

Review method

See how FormBlends checks viral health claims.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

View topic hubSemaglutide video claimsReview SemaglutideTreatment or product pathRead GLP-1 guideDeeper FormBlends guide

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Sierra's Wegovy weight loss tracking looks about right" from Sierra. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Sierra is documenting semaglutide use at the 1.

The reason this review is not generic is the source wording and the canonical claim label "glp1 my wegovy weight loss week by week with weights and graphs." In this clip, the useful excerpt is: "I've been on wagobi for the last month, so I'm going to share my weights and how much I lost week by week for the last four weeks." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Early semaglutide losses frequently include water weight, which can inflate week-one and week-two numbers significantly before slowing to a more modest fat-loss rate.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Sierra is documenting semaglutide use at the 1.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Sierra is documenting semaglutide use at the 1.0 mg dose, which sits within the standard Wegovy titration schedule that escalates from 0.25 mg up to the maintenance dose of 2.4 mg over several months. Her reported 8-pound loss over four weeks is plausible for an early treatment period, particularly given she was restarting after a gap, when appetite suppression effects can temporarily intensify. Her self-reported fatigue, which prompted a previous discontinuation, is a recognized side effect of GLP-1 receptor agonists and typically relates to caloric restriction and GI adaptation rather than a nutritional deficiency.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) found average semaglutide weight loss of 14.9% over 68 weeks, roughly 1-2 lbs per week on average, meaning Sierra's 3 lbs per week is above average and not a standard benchmark.
  • Early semaglutide losses frequently include water weight, which can inflate week-one and week-two numbers significantly before slowing to a more modest fat-loss rate.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The STEP 1 trial (Wilding et al., 2021, NEJM) found average semaglutide weight loss of 14.9% over 68 weeks, roughly 1-2 lbs per week on average, meaning Sierra's 3 lbs per week is above average and not a standard benchmark.
  • Early semaglutide losses frequently include water weight, which can inflate week-one and week-two numbers significantly before slowing to a more modest fat-loss rate.
  • Week-to-week weight fluctuations of 1-3 pounds are normal and do not signal medication failure. Factors like sodium, hormones, and hydration routinely shift the scale without any change in fat mass.
  • No published clinical evidence supports liquid B vitamins as a treatment for semaglutide-related fatigue. Fatigue typically resolves as the body adjusts to caloric restriction and GI side effects stabilize.
  • Two-thirds of weight lost on semaglutide is typically regained within one year of stopping the medication (Wilding et al., 2022, Diabetes, Obesity and Metabolism), a reality absent from most GLP-1 content on social media.
  • Wegovy's approved dosing escalates from 0.25 mg to 2.4 mg over 16-20 weeks. Results at 1.0 mg, where Sierra is currently, may differ from outcomes at the full therapeutic dose.
  • Individual variation in semaglutide response is wide. Using one person's four-week results to evaluate your own progress or set expectations is not clinically sound.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @sierra.robichaud actually say?

Sierra documented four weeks of weekly weigh-ins while taking semaglutide (Wegovy) at the 1.0 mg dose. She started at 180 pounds on May 6 and ended at 172 pounds, reporting a total loss of 8 pounds over the month. She also mentioned stopping Wegovy briefly due to fatigue, then restarting alongside liquid B vitamins, which she credited for feeling better on the medication. Her week-by-week breakdown: minus 3, minus 3, plus 1, minus 3.

She presented this casually and honestly, including the week she gained a pound. That kind of transparency is worth noting because most weight loss content on TikTok conveniently omits the bad weeks. She explicitly called 8 pounds in a month "pretty normal" for her while on the medication.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Sierra · TikTok creator

148.2K views on this video

My wegovy weight loss week by week with weights and graphs 🤓 #wegovy #wegovyweightloss #semaglutide #weightloss #weightlossjourney #glp1 #weeklyweighin #weeklyweightcheck

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial (wilding et al., 2021, nejm) found?

The STEP 1 trial (Wilding et al., 2021, NEJM) found average semaglutide weight loss of 14.9% over 68 weeks, roughly 1-2 lbs per week on average, meaning Sierra's 3 lbs per week is above average and not a standard benchmark.

What does the video say about early semaglutide losses frequently include water weight,?

Early semaglutide losses frequently include water weight, which can inflate week-one and week-two numbers significantly before slowing to a more modest fat-loss rate.

What does the video say about week-to-week weight fluctuations of 1-3 pounds?

Week-to-week weight fluctuations of 1-3 pounds are normal and do not signal medication failure. Factors like sodium, hormones, and hydration routinely shift the scale without any change in fat mass.

What does the video say about no published clinical evidence supports liquid b vitamins as a?

No published clinical evidence supports liquid B vitamins as a treatment for semaglutide-related fatigue. Fatigue typically resolves as the body adjusts to caloric restriction and GI side effects stabilize.

What does the video say about two-thirds of weight lost on semaglutide?

Two-thirds of weight lost on semaglutide is typically regained within one year of stopping the medication (Wilding et al., 2022, Diabetes, Obesity and Metabolism), a reality absent from most GLP-1 content on social media.

What does the video say about wegovy's approved dosing escalates from 0.25 mg to 2.4 mg?

Wegovy's approved dosing escalates from 0.25 mg to 2.4 mg over 16-20 weeks. Results at 1.0 mg, where Sierra is currently, may differ from outcomes at the full therapeutic dose.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Sierra, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.